Search research articles
Contact Us
Filters
Showing results (31-40 of 59) with videos related to
Page
of 6
Sort By:
Clinical Pharmacology in Drug Development
|
June 18, 2019
Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
Vikas Kumar Dawra, Yali Liang, Hua Wei, et al.
Clinical Pharmacokinetics
|
April 28, 2020
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Daryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, et al.
British Journal of Clinical Pharmacology
|
March 4, 2011
The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency
Haiqing Dai, Susan L Johnson, Steven G Terra, et al.
Clinical Pharmacology in Drug Development
|
November 15, 2018
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
Vaishali Sahasrabudhe, Daryl J Fediuk, Kyle Matschke, et al.
Current Therapeutic Research, Clinical and Experimental
|
December 9, 2024
US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients
Mark R Cullen, Xiaofeng Zhou, Scott P Kelly, et al.
Clinical Pharmacology in Drug Development
|
May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
Vikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 30, 2025
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
Wuyan Zhang, Steven G Terra, Edward Alan Weinstein, et al.
Current Medical Research and Opinion
|
February 15, 2019
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
Priscilla Hollander, Julie Hill, Jeremy Johnson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 29, 2017
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
Priscilla Hollander, Jie Liu, Julie Hill, et al.
Diabetes, Obesity & Metabolism
|
July 24, 2020
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies
Richard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 59) with videos related to
Sort By:
Page
of 6
Clinical Pharmacology in Drug Development
|
June 18, 2019
Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
Vikas Kumar Dawra, Yali Liang, Hua Wei, et al.
Clinical Pharmacokinetics
|
April 28, 2020
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Daryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, et al.
British Journal of Clinical Pharmacology
|
March 4, 2011
The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency
Haiqing Dai, Susan L Johnson, Steven G Terra, et al.
Clinical Pharmacology in Drug Development
|
November 15, 2018
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
Vaishali Sahasrabudhe, Daryl J Fediuk, Kyle Matschke, et al.
Current Therapeutic Research, Clinical and Experimental
|
December 9, 2024
US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients
Mark R Cullen, Xiaofeng Zhou, Scott P Kelly, et al.
Clinical Pharmacology in Drug Development
|
May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
Vikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 30, 2025
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
Wuyan Zhang, Steven G Terra, Edward Alan Weinstein, et al.
Current Medical Research and Opinion
|
February 15, 2019
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
Priscilla Hollander, Julie Hill, Jeremy Johnson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 29, 2017
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
Priscilla Hollander, Jie Liu, Julie Hill, et al.
Diabetes, Obesity & Metabolism
|
July 24, 2020
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies
Richard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, et al.
Page
of 6